Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Metoprolol vs. Atenolol for Hypertension Treatment

Pharmacological Differences

  • The American College of Cardiology notes that both metoprolol and atenolol are beta-1 selective adrenoceptor blockers without intrinsic sympathomimetic activity 3, 1
  • Metoprolol is available in immediate-release and sustained-release formulations, according to the American Heart Association 4, 5

Cardiovascular Outcomes

  • The American Heart Association recommends metoprolol over atenolol for hypertension treatment due to questioned cardiovascular benefits of atenolol 1, 2
  • Metoprolol succinate is preferred in patients with heart failure with reduced ejection fraction, as stated by the American College of Cardiology 4, 5

Dosing Considerations

  • The American Heart Association suggests metoprolol tartrate dosing at 100-200 mg twice daily for hypertension 4
  • Metoprolol succinate dosing is recommended at 50-200 mg once daily for hypertension, according to the American College of Cardiology 4

Special Populations

  • Both metoprolol and atenolol are cardioselective beta blockers, making them preferred in patients with bronchospastic airway disease requiring beta-blocker therapy, as noted by the American College of Cardiology 4, 5
  • In patients with significant chronic obstructive pulmonary disease, the American Heart Association recommends starting with low doses of a beta-1-selective agent like metoprolol 1, 2

Clinical Decision Making

  • For most hypertension patients, the American Heart Association recommends choosing metoprolol over atenolol due to questioned cardiovascular benefits of atenolol 1, 2
  • For patients with HFrEF, metoprolol succinate is specifically preferred, according to the American College of Cardiology 4, 5

Common Pitfalls

  • The American College of Cardiology warns that abrupt cessation of either beta-blocker should be avoided to prevent rebound hypertension or other adverse effects 4, 5
  • Beta blockers are not recommended as first-line agents for hypertension unless the patient has ischemic heart disease or heart failure, as stated by the American Heart Association 4, 5

REFERENCES